Treatment of migraine headache with botulinum toxin type A - 31/08/11
Doi : 10.1016/S1064-7406(03)00076-2
William J Binder, MD, FACS ⁎, a, b 
, Andrew Blitzer, DDS, MD, FACS c
, Andrew Blitzer, DDS, MD, FACS c a Department of Head and Neck Surgery, University of California at Los Angeles School of Medicine, USA
b Department of Otolaryngology/Head and Neck Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA
c Department of Otolaryngology and Head and Neck Surgery, Columbia Presbyterian Medical Center, New York, NY, USA
*Corresponding author. 120 South Spalding Drive, Suite 340, Beverly Hills, CA 90212
Plan
 | Disclosures: Drs. Binder and Blitzer have financial interests associated with intellectual property related to botulinum toxin. Both are consultants to Allergan Corporation. |
© 2003
Elsevier Inc. Tous droits réservés.
Vol 11 - N° 4
P. 465-475 - novembre 2003 Retour au numéro
Article précédent
- Altering brow contour with botulinum toxin
- Achih H Chen, Andrew S Frankel
- Adjunctive applications for botulinum toxin in facial aesthetic surgery
- Marc S Zimbler, Paul S Nassif
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?